Novo Nordisk reports breach of deidentified patient trial data

NOVO Nordisk, a major biopharma company, has reported a data breach involving its internal IT systems. The breach affected a limited amount of de-identified patient data from clinical trials, including patients' birth years, biomarkers, and lifestyle factors, but no direct identifiers like names. The company noted that this data was copied externally without authorization. Novo's notice urges patients to remain vigilant regarding their information.